40515-98-8

Basic information

• Product Name: LP 8 (pharmaceutical)
• Synonyms: 2-(2',6'-dimethoxyphenoxy)ethylamine;2-(2,6-dimethoxy)phenoxy-1-aminoethane;2-(2,6-dimethoxy-phenoxy)ethylamine;2-(2,6-dimethoxyphenoxy)-1-ethanamine;2-(2,6-dimethoxyphenoxy)ethanamine;LP 8
• CAS NO: 40515-98-8
• Molecular Formula: C10H15NO3
• Molecular Weight: 197.234
• Mol File: 40515-98-8.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: LP 8 (pharmaceutical)(CAS DataBase Reference)
• NIST Chemistry Reference: LP 8 (pharmaceutical)(40515-98-8)
• EPA Substance Registry System: LP 8 (pharmaceutical)(40515-98-8)

Safety Data

• Hazardous Substances Data: 40515-98-8(Hazardous Substances Data)

Upstream product

• 59825-50-2 1-bromo-2-<(2,6-dimethoxy)phenoxy>ethane 
• 91-10-1 1,3-dimethoxy-2-hydroxy-benzene 
• 87780-28-7 N-[2-(2,6-dimethoxy-phenoxy)-ethyl]-phthalimide 

Downstream Products

• 96649-40-0 N²-[2-(2,6-Dimethoxy-phenoxy)-ethyl]-6,7-dimethoxy-quinazoline-2,4-diamine 
• 81602-24-6 (R)-WB-4101 
• 77133-43-8 (S)-WB-4101 
• 753023-11-9 (2S)-2-[((2-(2,6-dimethoxyphenoxy)ethyl)amino)methyl]-2,3-dihydronaphtho[2,3-b][1,4]dioxine 
• 753023-12-0 (2S)-2-[((2-(2,6-dimethoxyphenoxy)ethyl)amino)methyl]-2,3,6,7,8,9-hexahydronaphtho[2,3-b][1,4]dioxine 

Relevant articles and documents

An integrative study to identify novel scaffolds for sphingosine kinase 1 inhibitors

Sphingosine kinase 1 (SphK1), the enzyme that produces the bioactive sphingolipid metabolite, sphingosine-1-phosphate, is a promising new molecular target for therapeutic intervention in cancer and inflammatory diseases. In view of its importance, the main objective of this work was to find new and more potent inhibitors for this enzyme possessing different structural scaffolds than those of the known inhibitors. Our theoretical and experimental study has allowed us to identify two new structural scaffolds (three new compounds), which could be used as starting structures for the design and then the development of new inhibitors of SphK1. Our study was carried out in different steps: virtual screening, synthesis, bioassays and molecular modelling. From our results, we propose a new dihydrobenzo[b]pyrimido[5,4-f]azepine and two alkyl{3-/4-[1-hydroxy-2-(4-arylpiperazin-1-yl)ethyl]phenyl}carbamates as initial structures for the development of new inhibitors. In addition, our molecular modelling study using QTAIM calculations, allowed us to describe in detail the molecular interactions that stabilize the different Ligand-Receptor complexes. Such analyses indicate that the cationic head of the different compounds must be refined in order to obtain an increase in the binding affinity of these ligands.

Synthesis and pharmacological activity of a new series of 1-(1H-indol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)-propan-2-ol analogs

β-Adrenergic receptor antagonists are important therapeutics for the treatment of cardiovascular disorders. In the group of β-blockers, much attention is being paid to the third-generation drugs that possess important ancillary properties besides inhibiting β-adrenoceptors. Vasodilating activity of these drugs is produced through different mechanisms, such as nitric oxide (NO) release, β2-agonistic action, α1-blockade, antioxidant action, and Ca2t entry blockade. Here, a study on evaluation of the cardiovascular activity of five new compounds is presented. Compound 3a is a methyl and four of the tested compounds (3b–e) are dimethoxy derivatives of 1-(1H-indol-4-yloxy)-3-(2-(2-methoxyphenoxy)-ethylamino)propan-2-ol. The obtained results confirmed that the methyl and dimethoxy derivatives of 1-(1H-indol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)propan-2-ol and their enantiomers possess α1- and β1-adrenolytic activities and that the antiarrhythmic and hypotensive effects of the tested compounds are related to their adrenolytic properties.

Synthesis and pharmacological evaluation of some WB4101 analogues bearing a naphtodioxanic nucleus

-